Last reviewed · How we verify
NCT07104058
A Study on the Effect of MRD Detected by FAPI PET / CT on the Recurrence of IgG4-RD
NA trial testing 68Ga-FAPI PET / CT in IgG4-Related Diseases in 46 participants. Currently enrolling.
1 December 2027
Quick facts
| Lead sponsor | Luo Yaping |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 46 |
| Start date | 10 May 2025 |
| Primary completion | 1 December 2027 |
| Estimated completion | 1 December 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- 68Ga-FAPI PET / CT
Conditions studied
- IgG4-Related Diseases — all drugs for IgG4-Related Diseases →
Sponsor
Luo Yaping
Who can join
Adults 18 to 75, any sex, with IgG4-Related Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study intends to use the new technology of fibroblast activation protein PET / CT to study whether the tiny residual lesions detected by 68Ga-FAPI PET / CT are related to the recurrence of IgG4-RD in patients with IgG4-RD who have been clinically evaluated for complete remission after treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07104058
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for IgG4-Related Diseases
Currently open trials in the same condition.
- NCT06978647 — A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases · Phase 1 · recruiting
- NCT06794008 — BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases · Phase 2 · recruiting
- NCT06285279 — The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases · Phase 1 · recruiting
Other Luo Yaping trials
Trials by the same sponsor.
- NCT06973798 — The Study on the Effectiveness of [68Ga]Ga-HBED-CC-DiAsp PET/CT in Calculating GFR and Predicting Residual Renal Functio · NA · not yet recruiting
- NCT07138716 — Research on the Application of 68Ga-DOTA-CCK-FS PET/CT in MTC · NA · recruiting
- NCT07138729 — Research on the Application of 99mTc-TCR-FAPI SPECT Imaging in Rheumatoid Arthritis · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07104058 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Luo Yaping
- Last refreshed: 5 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07104058.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing